AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03484247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
Study NCT03484247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: axillary brachial plexus block
Description: Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
Study NCT03782701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution 0.025%
Description: One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
Study NCT03782701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile balanced saline solution
Description: One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
Study NCT03306992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Exercise Program
Description: The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (\~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention.
Study NCT01994616 — intervention group
Intervention type: PROCEDURE
Intervention: Intralesional cryotherapy
Description: Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
Study NCT01761448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guide Exercise (GEx-)- Training
Description: Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
Study NCT01761448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity
Study NCT01761448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group training without Guided Exercise system at home
Study NCT02023957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive computer-assisted screening (iCAS)
Study NCT01442714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death
Study NCT01442714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
Study NCT02154919 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Study NCT04054141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mag Stim
Description: rTMS
Study NCT00694018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and standard care
Description: Educational program for individuals with chronic back pain.
Study NCT00694018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and standard care
Description: Educational program for individuals with chronic back pain.
Study NCT00694018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet mediated enhanced pedometer intervention
Description: Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
Study NCT02674347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 g or 6 g Zidebactam
Description: IV for over a duration of 60 minutes
Study NCT02674347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV matching the Investigational drug
Study NCT00622505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
Study NCT04577430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
Study NCT04577430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
Study NCT04577430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
Study NCT04577430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
Study NCT04486014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Erector Spinae Group (Group E) will receive bilateral ultrasound-guided erector spinae plane block using 30 ml hyperbaric bupivacaine 0.25% will be injected between erector spinae muscle and transverse process of T4
Study NCT04486014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Description: Serratus anterior Group (Group S) will undergo bilateral ultrasound-guided serratus anterior plane block with 30 ml hyperbaric bupivacaine 0.25% will be injected above or below serratus anterior muscle at the level of 4th and 5th rib on the midaxillary line
Study NCT04054076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated insoles
Description: The participants received prefabricated insoles
Study NCT04054076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft custom-made insoles
Description: The participants received soft custom-made insoles
Study NCT04054076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hard custom-made insoles
Description: The participants received hard custom-made insoles
Study NCT02094092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ProTectis drops (five drops per day) for 21 days
Study NCT02094092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops (five drops per day) for 21 days
Study NCT00933868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride
Description: An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
Study NCT00933868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 2
Description: Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 3
Description: Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 4
Description: Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 5
Description: Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 6
Description: Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
Study NCT04336072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RFPP
Study NCT04336072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TFCBT
Study NCT03863431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat diet
Description: Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study.
Study NCT03863431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-carbohydrate diet
Description: Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study.
Study NCT04498442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simha Kriya
Description: Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.
Study NCT04498442 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reading a Book
Description: Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.
Study NCT04131179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)
Description: Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness.
Study NCT04574401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-002
Description: Intravenous injection of IS-002 Investigational Drug
Study NCT03372967 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccine administration by a pharmacist
Description: Administration, number and types, of vaccines by a pharmacist
Study NCT03372967 — intervention group
Intervention type: BEHAVIORAL
Intervention: Unmet vaccination needs identified and met
Description: Identification of unmet vaccination needs and having those needs met
Study NCT03372967 — intervention group
Intervention type: BEHAVIORAL
Intervention: Vaccination forecast review and patient education
Description: Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
Study NCT01602289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2875358
Description: Administered IV
Study NCT01602289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered orally
Study NCT01602289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Administered orally
Study NCT02076282 — intervention group
Intervention type: OTHER
Intervention: 1 MRI scan
Description: For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast
Study NCT02960607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 7
Description: Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 8
Description: Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
Study NCT03346122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 9
Description: Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
Study NCT01812928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT04376034 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma 1 Unit
Description: Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma.
Study NCT04376034 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma 2 Units
Description: Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma.
Study NCT04376034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
Study NCT01215968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: 1.5 mg administered subcutaneously
Study NCT01215968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously
Study NCT01215968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT03250728 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peripheral blood puncture
Description: Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system
Study NCT02155816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 7 + 3
Description: Ingestion of omega 7 + 3 daily for 8 weeks.
Study NCT02155816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega 3 daily for 8 weeks.
Study NCT02155816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medium chain triglycerides
Study NCT01566747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800mg day to be given continuously until disease progression.
Study NCT00118872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGG yogurt
Description: Lactobacillus GG containing yogurt
Study NCT00118872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo yogurt
Description: Yogurt NOT containing the active LGG bacteria
Study NCT00960492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
Study NCT00960492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
Study NCT00960492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
Study NCT00960492 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
Study NCT00960492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
Study NCT04464434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upfront autologous HSCT
Description: HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg.
Study NCT02692755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole or Fulvestrant
Description: Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
Study NCT03387020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT03387020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03387020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03387020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT04236362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT04236362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor
Study NCT02770924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LISA TRI TORIC
Description: phacoemulsification with IOL implantation
Study NCT03651791 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: USPIO labeled MSC injection
Description: USPIO labeled MSC injection